Natalizumab treatment for multiple sclerosis

Ferreira, Maria Lúcia Brito

doi:10.1590/0004-282x20140198

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug was suspended from the market because of two cases of PML. After considerable scrutiny of these PML cases, natalizumab again became available in 2006, but only after the FDA mandated careful monitoring and surveillance for PML through the TOUCH programme 82-84. Overall, clinical experiences, as well as patient registry studies, such as the TYSABRI Observational Program or MSBase, have confirmed the superiority of natalizumab over IFN-β and GA; however, the cases of PML in natalizumab treated patients have been increasing at an alarming rate.…”

Section: Intravenous Dmtsmentioning

confidence: 99%

Update on Disease-Modifying Therapies for Multiple Sclerosis

Vargas

Tyor

2017

Journal of Investigative Medicine

116

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system (CNS). It predominantly affects young women and is one of the most common causes of disability in young adults. MS is characterized by formation of white matter lesions in the CNS as a result of inflammation, demyelination, and axonal loss. Treatment has been a focus of neurological research for over 60 years. A number of disease-modifying therapies (DMTs) have become available making MS a treatable disease. These compounds target the inflammatory response in MS. They work by decreasing the chances of relapse, decreasing the chances of new lesion formation seen on MRI of the CNS and slowing the accumulation of disability. The first drugs for MS to be available were interferon-β and glatiramer acetate. These work by modulating the inflammatory response via different mechanisms that are briefly discussed. Newer agents have since become available and have significantly changed the dynamics of MS treatment. These include fingolimod, dimethyl fumarate and teriflunomide, which are oral agents. Other second-line and thirdline Food and Drug Administration (FDA) approved medications include natalizumab and alemtuzumab.

show abstract

Section: Intravenous Dmtsmentioning

confidence: 99%